Arsanis, Inc. (ASNS)

Recent filings

Bihua Chen just provided an update on share ownership of Arsanis, Inc. - Feb. 14, 2020

EcoR just provided an update on share ownership of Arsanis, Inc. - Feb. 14, 2020

Departure of Directors or Certain - Feb. 13, 2020

James E. Flynn just provided an update on share ownership of Arsanis, Inc. - Feb. 13, 2020

Results of Operations and Financial - Jan. 10, 2020

EcoR just provided an update on share ownership of Arsanis, Inc. - Dec. 17, 2019

BCIP Life Sciences Associates, LP just provided an update on share ownership of Arsanis, Inc. - Dec. 9, 2019

James E. Flynn just provided an update on share ownership of Arsanis, Inc. - Dec. 3, 2019

Arsanis: X4 Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Class B Warrants - Nov. 27, 2019

Arsanis, Inc.'s General Counsel was just granted 55,000 options - Nov. 27, 2019

Filing under Securities Act Rules 163/433 of free writing prospectuses - Nov. 26, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 25, 2019

Entry into a Material Definitive - Nov. 14, 2019

Arsanis, Inc. Just Filed Its Quarterly Report: Net Income (Loss) pe... - Nov. 7, 2019

Arsanis: X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Highlights - Nov. 7, 2019

Arsanis, Inc.'s General Counsel just declared ownership of no shares of Arsanis, Inc. - Nov. 6, 2019

Departure of Directors or Certain - Oct. 18, 2019

Regulation FD Disclosure - Oct. 4, 2019

Arsanis: X4 Pharmaceuticals Reports Positive Data From Phase 2A Trial Of Mavorixafor In Combination With Axitinib In Advanced Clear Cell Renal Cell Carcinoma Patients - Sept. 30, 2019

Arsanis, Inc. director was just granted 6,854 options - Sept. 20, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - Sept. 20, 2019

Departure of Directors or Certain - Sept. 20, 2019

Arsanis, Inc. Just Received a Notice of Effectiveness - Aug. 29, 2019

Registration statement under Securities Act of 1933 - Aug. 22, 2019

Securities to be offered to employees in employee benefit plans - Aug. 9, 2019

Registration statement under Securities Act of 1933 - Aug. 9, 2019

Arsanis: X4 ManagementÂ’S Discussion And Analysis Of FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Aug. 9, 2019

Terrance G. McGuire just provided an update on activist position in Arsanis, Inc. - July 17, 2019

Entry into a Material Definitive - June 28, 2019

Arsanis: X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial Of Mavorixafor For The - June 26, 2019

Departure of Directors or Certain - June 19, 2019

Arsanis, Inc. director was just granted 3,427 options - June 19, 2019

Arsanis, Inc. director was just granted 3,427 options - June 19, 2019

Arsanis, Inc.'s CFO and Treasurer just picked up 10,564 shares - June 19, 2019

Arsanis, Inc.'s President and CEO just picked up 55,928 shares - June 19, 2019

General statement of acquisition of beneficial ownership - May 28, 2019

Arsanis, Inc. releases salary data. CEO sees compensation rise 21% - May 22, 2019

Departure of Directors or Certain - May 17, 2019

Arsanis, Inc. Just Filed Its Quarterly Report: 15. Net Loss per... - May 15, 2019

Financial Statements and - May 13, 2019

Statement of acquisition of beneficial ownership by individuals - May 10, 2019

Arsanis, Inc.'s Chief Medical Officer was just granted 37,170 options - April 26, 2019

Arsanis, Inc.'s See Remarks just declared ownership of no shares of Arsanis, Inc. - April 26, 2019

Paula Ragan, Ph.D. just provided an update on activist position in Arsanis, Inc. - April 26, 2019

Mark N. Lampert just provided an update on share ownership of Arsanis, Inc. - April 23, 2019

Bihua Chen just provided an update on share ownership of Arsanis, Inc. - April 22, 2019

OrbiMed Advisors LLC just provided an update on share ownership of Arsanis, Inc. - April 19, 2019

James E. Flynn just provided an update on share ownership of Arsanis, Inc. - April 16, 2019

Arsanis: X4 Pharmaceuticals Prices $85.8 Million Public Offering Of Common Stock And Class A Warrants - April 15, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - April 15, 2019

Filing under Securities Act Rules 163/433 of free writing prospectuses - April 12, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - April 12, 2019

Arsanis: X4 Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Class A Warrants - April 12, 2019

Arsanis: Description Of The Business Of X4 Pharmaceuticals, Inc Overview - April 11, 2019

Arsanis: Index To Consolidated Financial Statements - April 3, 2019

Arsanis, Inc. director was just granted 28,424 options - April 2, 2019

Arsanis, Inc. director was just granted 77,650 options - April 2, 2019

Arsanis, Inc. director was just granted 77,178 options - April 2, 2019

Arsanis, Inc. director was just granted 6,854 options - April 2, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - April 2, 2019

Departure of Directors or Certain - April 2, 2019

Arsanis: Genetic Mutations In Cxcr4 Create Abnormal Trafficking Of White Blood Cells (Wbcs) - April 1, 2019

Securities to be offered to employees in employee benefit plans - March 25, 2019

Paula Ragan, Ph.D. just provided an update on activist position in Arsanis, Inc. - March 22, 2019

OrbiMed Capital GP IV LLC just provided an update on activist position in Arsanis, Inc. - March 19, 2019

Arsanis, Inc.'s See Remarks was just granted 62,633 options - March 15, 2019

Melinda French Gates just provided an update on share ownership of Arsanis, Inc. - March 15, 2019

Arsanis, Inc. director was just granted 21,570 options - March 14, 2019

Arsanis, Inc. director was just granted 70,796 options - March 14, 2019

Arsanis, Inc. director was just granted 70,324 options - March 14, 2019

Arsanis, Inc.'s See Remarks was just granted 62,633 options - March 14, 2019

Arsanis, Inc.'s President and CEO just picked up 181,366 shares - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc.'s See Remarks just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc.'s President and CEO just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

X4 Pharmaceuticals Completes Merger With Arsanis - March 13, 2019

Securities to be offered to employees in employee benefit plans - March 11, 2019

Arsanis, Inc. Just Filed Its Annual Report: 15. Net Loss pe... - March 11, 2019

Arsanis: Fee Computed On Table Below Per Exchange Act Rules - March 8, 2019

Entry into a Material Definitive - March 8, 2019

Prospectuses and communications, business combinations - March 8, 2019

Termination of a Material Definitive - March 1, 2019

Prospectuses and communications, business combinations - March 1, 2019

Arsanis: Fee Computed On Table Below Per Exchange Act Rules - March 1, 2019

Arsanis, Inc. Just Received a Notice of Effectiveness - Feb. 19, 2019

Arsanis, Inc. Just Received a Notice of Effectiveness - Feb. 14, 2019

Registration of securities, business combinations - Feb. 13, 2019

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an - Feb. 8, 2019

Registration statement under Securities Act of 1933 - Jan. 25, 2019

Departure of Directors or Certain - Jan. 16, 2019

Registration of securities, business combinations - Dec. 20, 2018

Prospectuses and communications, business combinations - Dec. 20, 2018

Entry into a Material Definitive - Dec. 20, 2018

just provided an update on activist position in Arsanis, Inc. - Dec. 6, 2018

President of Arsanis, Inc. just picked up 250,000 shares - Nov. 28, 2018

Prospectuses and communications, business combinations - Nov. 27, 2018

Arsanis, Inc. And X4 Pharmaceuticals, Inc. Conference Call - Nov. 27, 2018

Arsanis: Phase 3 Trial Of X4P-001 In Whim – Expected Initiation In 1H 2019 Meets Entry Criteria X4P-001 (N=9) Placebo (N=9) 52 Weeks Establish Auc Baseline 1 - Nov. 27, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. BlackRock Inc. 254,180 N/A Dec. 31, 2018
2. JPMORGAN CHASE & CO 232,596 N/A Dec. 31, 2017
3. BlackRock Inc. 226,638 N/A Sept. 30, 2018
4. CITIGROUP INC 126,435 N/A Sept. 30, 2018
5. NORTHERN TRUST CORP 54,563 N/A Dec. 31, 2018
6. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
7. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
8. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
9. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
10. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
11. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
12. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
13. NORTHERN TRUST CORP 32,097 N/A March 31, 2018
14. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
15. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
16. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
17. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
18. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
19. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
20. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
21. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
22. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
23. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
24. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
25. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
26. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
27. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
28. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
29. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
30. MORGAN STANLEY 13,387 N/A Sept. 30, 2018

Arsanis, Inc. (ASNS)

140

cctranscripts

Feb. 14, 2020

EcoR just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7442962

cctranscripts

Feb. 14, 2020

Bihua Chen just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7444196

cctranscripts

Feb. 13, 2020

Departure of Directors or Certain http://www.conferencecalltranscripts.org/pink/summary?id=7431298

cctranscripts

Feb. 13, 2020

James E. Flynn just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7429604

cctranscripts

Jan. 10, 2020

Results of Operations and Financial http://www.conferencecalltranscripts.org/pink/summary?id=7276817

cctranscripts

Dec. 17, 2019

EcoR just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7196520

cctranscripts

Dec. 9, 2019

BCIP Life Sciences Associates, LP just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7164177

cctranscripts

Dec. 3, 2019

James E. Flynn just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7141272

cctranscripts

Nov. 27, 2019

Arsanis, Inc.'s General Counsel was just granted 55,000 options http://www.conferencecalltranscripts.org/pink/summary?id=7116581

cctranscripts

Nov. 27, 2019

Arsanis: X4 Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Class B Warrants http://www.conferencecalltranscripts.org/pink/summary?id=7117356

cctranscripts

Nov. 26, 2019

Filing under Securities Act Rules 163/433 of free writing prospectuses http://www.conferencecalltranscripts.org/pink/summary?id=7107618

cctranscripts

Nov. 25, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities http://www.conferencecalltranscripts.org/pink/summary?id=7103556

cctranscripts

Nov. 14, 2019

Entry into a Material Definitive http://www.conferencecalltranscripts.org/pink/summary?id=7061130

cctranscripts

Nov. 7, 2019

Arsanis: X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Highlights http://www.conferencecalltranscripts.org/pink/summary?id=7021116

cctranscripts

Nov. 7, 2019

Arsanis, Inc. Just Filed Its Quarterly Report: Net Income (Loss) pe... http://www.conferencecalltranscripts.org/pink/summary?id=7024889

cctranscripts

Nov. 6, 2019

Arsanis, Inc.'s General Counsel just declared ownership of no shares of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7017066

cctranscripts

Oct. 18, 2019

Departure of Directors or Certain http://www.conferencecalltranscripts.org/pink/summary?id=6936848

cctranscripts

Oct. 4, 2019

Regulation FD Disclosure http://www.conferencecalltranscripts.org/pink/summary?id=6892736

cctranscripts

Sept. 30, 2019

Arsanis: X4 Pharmaceuticals Reports Positive Data From Phase 2A Trial Of Mavorixafor In Combination With Axitinib In Advanced Clear Cell Renal Cell Carcinoma Patients http://www.conferencecalltranscripts.org/pink/summary?id=6866448

cctranscripts

Sept. 20, 2019

Arsanis, Inc. director was just granted 6,854 options http://www.conferencecalltranscripts.org/pink/summary?id=6837798
 


Feedback